Uduak U Andy1, Heidi S Harvie1, Ariana L Smith2, Kathleen J Propert3, Hillary R Bogner4, Lily A Arya1. 1. Division of Urogynecology, Department of Obstetrics and Gynecology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania. 2. Division of Urology, Department of Surgery, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania. 3. Department of Biostatistics and Epidemiology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania. 4. Department of Family Medicine and Community Health, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania.
Abstract
AIM: To validate a self-administered instrument, the Medication Adherence Self-Report Inventory (MASRI) for measuring adherence to anti-cholinergic medication for overactive bladder (OAB). METHODS: Prospective study in 131 women with OAB treated with fesoterodine. Adherence was measured at 8 and 12 weeks using an interviewer administered brief medication questionnaire (BMQ) that assesses barriers to adherence (criterion standard), the MASRI, and pill count. Construct, concurrent and discriminant validity of the MASRI was assessed. We hypothesized that women who were non-adherent as measured by the MASRI would be more likely to have a belief barrier than women who were adherent to medication. RESULTS: Women diagnosed as non-adherent by the MASRI were more likely to report a belief barrier to taking medication as compared to adherent women at 8 weeks (80% vs. 38%, P < 0.001) and at 12 weeks (70% vs. 40%, P = 0.003). Significant correlations were noted between adherence rates measured by the MASRI and the BMQ at 8 weeks (r = 0.87, P < 0.001) and 12 weeks (r = 0.90, P < 0.001). Moderate correlation was noted between the adherence rate as measured by the MASRI and pill count at 8 weeks (r = 0.49, P = 0.02) but not at 12 weeks (r = 0.05, P = 0.87). The MASRI correctly identified 93% and 96% of non-adherent women at 8 and 12 weeks, respectively. Sensitivity, specificity, and positive likelihood ratio of the MASRI for predicting non-adherence was 91%, 82%, and 5.1 at 8 weeks and 90%, 85% and 6.1 at 12 weeks. CONCLUSIONS: The MASRI is a valid self-administered tool for measuring adherence to anti-cholinergic medication in women with OAB.
AIM: To validate a self-administered instrument, the Medication Adherence Self-Report Inventory (MASRI) for measuring adherence to anti-cholinergic medication for overactive bladder (OAB). METHODS: Prospective study in 131 women with OAB treated with fesoterodine. Adherence was measured at 8 and 12 weeks using an interviewer administered brief medication questionnaire (BMQ) that assesses barriers to adherence (criterion standard), the MASRI, and pill count. Construct, concurrent and discriminant validity of the MASRI was assessed. We hypothesized that women who were non-adherent as measured by the MASRI would be more likely to have a belief barrier than women who were adherent to medication. RESULTS:Women diagnosed as non-adherent by the MASRI were more likely to report a belief barrier to taking medication as compared to adherent women at 8 weeks (80% vs. 38%, P < 0.001) and at 12 weeks (70% vs. 40%, P = 0.003). Significant correlations were noted between adherence rates measured by the MASRI and the BMQ at 8 weeks (r = 0.87, P < 0.001) and 12 weeks (r = 0.90, P < 0.001). Moderate correlation was noted between the adherence rate as measured by the MASRI and pill count at 8 weeks (r = 0.49, P = 0.02) but not at 12 weeks (r = 0.05, P = 0.87). The MASRI correctly identified 93% and 96% of non-adherent women at 8 and 12 weeks, respectively. Sensitivity, specificity, and positive likelihood ratio of the MASRI for predicting non-adherence was 91%, 82%, and 5.1 at 8 weeks and 90%, 85% and 6.1 at 12 weeks. CONCLUSIONS: The MASRI is a valid self-administered tool for measuring adherence to anti-cholinergic medication in women with OAB.
Authors: Hernando Knobel; Jordi Alonso; José L Casado; Julio Collazos; Juan González; Isabel Ruiz; José M Kindelan; Alexia Carmona; Javier Juega; Antonio Ocampo Journal: AIDS Date: 2002-03-08 Impact factor: 4.177
Authors: W F Stewart; J B Van Rooyen; G W Cundiff; P Abrams; A R Herzog; R Corey; T L Hunt; A J Wein Journal: World J Urol Date: 2002-11-15 Impact factor: 4.226
Authors: Uduak U Andy; Lily A Arya; Ariana L Smith; Kathleen J Propert; Hillary R Bogner; Kristen Colavita; Heidi S Harvie Journal: Neurourol Urodyn Date: 2015-05-20 Impact factor: 2.696
Authors: Kirill V Kosilov; Sergay A Loparev; Irina G Kuzina; Olga V Shakirova; Yuliya I Gainullina; Liliya V Kosilova; Alexandra S Prokofyeva Journal: Arab J Urol Date: 2017-11-16
Authors: Yu Heng Kwan; Livia Jia Yi Oo; Dionne Hui Fang Loh; Truls Østbye; Lian Leng Low; Hayden Barry Bosworth; Julian Thumboo; Jie Kie Phang; Si Dun Weng; Dan V Blalock; Eng Hui Chew; Kai Zhen Yap; Corrinne Yong Koon Tan; Sungwon Yoon; Warren Fong Journal: J Med Internet Res Date: 2020-10-08 Impact factor: 5.428
Authors: Yu Heng Kwan; Si Dun Weng; Dionne Hui Fang Loh; Truls Østbye; Lian Leng Low; Hayden Barry Bosworth; Julian Thumboo; Jie Kie Phang; Livia Jia Yi Oo; Dan V Blalock; Eng Hui Chew; Kai Zhen Yap; Corrinne Yong Koon Tan; Sungwon Yoon; Warren Fong Journal: J Med Internet Res Date: 2020-10-09 Impact factor: 5.428
Authors: Cheryl L Tran; David T Selewski; Gia J Oh; Jonathan P Troost; Susan F Massengill; Samhar I Al-Akash; Shefali Mahesh; Rasheda Amin; Isa F Ashoor; Rahul Chanchlani; Mahmoud Kallash; Robert P Woroniecki; Debbie S Gipson Journal: Front Pediatr Date: 2021-02-05 Impact factor: 3.418